- Home
- CANF vs IPDN Comparison
CANF vs IPDN Comparison
Compare CANF & IPDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- IPDN
- Stock Information
- Founded
- CANF 1994
- IPDN 2003
- Country
- CANF Israel
- IPDN United States
- Employees
- CANF N/A
- IPDN N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- IPDN EDP Services
- Sector
- CANF Health Care
- IPDN Technology
- Exchange
- CANF Nasdaq
- IPDN Nasdaq
- Market Cap
- CANF 9.4M
- IPDN 10.2M
- IPO Year
- CANF N/A
- IPDN 2013
- Fundamental
- Price
- CANF $1.54
- IPDN $0.39
- Analyst Decision
- CANF Strong Buy
- IPDN
- Analyst Count
- CANF 2
- IPDN 0
- Target Price
- CANF $14.00
- IPDN N/A
- AVG Volume (30 Days)
- CANF 117.2K
- IPDN 394.7K
- Earning Date
- CANF 02-03-2025
- IPDN 11-14-2024
- Dividend Yield
- CANF N/A
- IPDN N/A
- EPS Growth
- CANF N/A
- IPDN N/A
- EPS
- CANF N/A
- IPDN N/A
- Revenue
- CANF $667,000.00
- IPDN $7,005,632.00
- Revenue This Year
- CANF $409.56
- IPDN N/A
- Revenue Next Year
- CANF N/A
- IPDN N/A
- P/E Ratio
- CANF N/A
- IPDN N/A
- Revenue Growth
- CANF N/A
- IPDN N/A
- 52 Week Low
- CANF $1.29
- IPDN $0.38
- 52 Week High
- CANF $4.69
- IPDN $3.01
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- IPDN 35.23
- Support Level
- CANF $1.55
- IPDN $0.38
- Resistance Level
- CANF $1.64
- IPDN $0.59
- Average True Range (ATR)
- CANF 0.10
- IPDN 0.07
- MACD
- CANF 0.01
- IPDN 0.00
- Stochastic Oscillator
- CANF 11.76
- IPDN 4.03
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.